Testbed 3: iPSC-derived Cells

A unique challenge in the iPSC-derived cell Test-Bed is the monitoring and control of cell differentiation state during manufacturing. Starting in Year 6, we have expanded the iPSC-derived cardiomyocyte Test-Bed to recognize the importance of other iPSC-derived cells and iPSC-derived products (extracellular vesicles) in response to industry partners’ interests.  Our projects address challenges in iPSC scale and cell differentiation for a variety of iPSC-derived products:

Projects

•    Assessing and Predicting Potency during iPSC Differentiation (Thrusts 1,2,3)

•    Scalable Manufacturing of iPSC-derived Cardiac Cells (Thrusts 1,2,3)

•    Manufacturing iPSC-derived CNS Models and Extracellular Vesicle (EV) Therapeutics (Thrusts 1,2,3)

Project Descriptions

• Test-Beds 3: Center to Centre: Ambient-temperature transport of therapeutic cells (Thrust Involved: 3)
• Test-Bed 3: Assessing and Predicting Potency during iPSC Differentiation (Thrust Involved: 1)
• Test-Bed 1 & 3: Systems engineering to manufacture off-the-shelf immunotherapies from iPS cells (Thrust Involved: 3)
• Test-Bed 3: Manufacturing iPSC-derived CNS Models and Extracellular Vesicle (EV) Therapeutics (Thrust Involved: 2)
• Test-Bed 3: Scalable Manufacturing of iPSC-derived Cardiac Cells (Primary Thrust Involved: 3)